[{"id":"3d373e1f-fe2b-41f0-84e9-9ccc47be3cca","acronym":"Pangeia-2","url":"https://clinicaltrials.gov/study/NCT06417801","created_at":"2024-05-18T04:15:22.395Z","updated_at":"2025-02-25T15:14:39.218Z","phase":"","brief_title":"Prevalence of Emerging Treatment-induced Mutations in Metastatic ER-positive Breast Cancer.","source_id_and_acronym":"NCT06417801 - Pangeia-2","lead_sponsor":"AstraZeneca","biomarkers":" ER","pipe":" | ","alterations":" ER mutation • ESR1 mutation","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER mutation • ESR1 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 06/17/2024","start_date":" 06/17/2024","primary_txt":" Primary completion: 12/30/2025","primary_completion_date":" 12/30/2025","study_txt":" Completion: 12/30/2025","study_completion_date":" 12/30/2025","last_update_posted":"2025-02-13"},{"id":"8637b136-3de4-40fa-8293-aa26c472595a","acronym":"SERENA-6","url":"https://clinicaltrials.gov/study/NCT04964934","created_at":"2021-07-16T13:53:17.689Z","updated_at":"2024-07-02T16:34:59.080Z","phase":"Phase 3","brief_title":"Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)","source_id_and_acronym":"NCT04964934 - SERENA-6","lead_sponsor":"AstraZeneca","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HR positive • HER-2 negative • ER mutation • ESR1 mutation • HR positive + HER-2 negative • PTEN mutation + HR positive","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HR positive • HER-2 negative • ER mutation • ESR1 mutation • HR positive + HER-2 negative • PTEN mutation + HR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • Verzenio (abemaciclib) • Kisqali (ribociclib) • letrozole • anastrozole • camizestrant (AZD9833)"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 06/30/2021","start_date":" 06/30/2021","primary_txt":" Primary completion: 04/25/2025","primary_completion_date":" 04/25/2025","study_txt":" Completion: 11/26/2027","study_completion_date":" 11/26/2027","last_update_posted":"2024-06-04"},{"id":"348b6bee-e334-487c-b8b5-38e99c466308","acronym":"ADELA","url":"https://clinicaltrials.gov/study/NCT06382948","created_at":"2024-04-24T17:32:40.686Z","updated_at":"2024-07-02T16:35:07.380Z","phase":"Phase 3","brief_title":"Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.","source_id_and_acronym":"NCT06382948 - ADELA","lead_sponsor":"MedSIR","biomarkers":" HER-2 • ER • CDK4","pipe":" | ","alterations":" HER-2 mutation • ER mutation • ESR1 mutation • CDK4 mutation","tags":["HER-2 • ER • CDK4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 mutation • ER mutation • ESR1 mutation • CDK4 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • Orserdu (elacestrant)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 240","initiation":"Initiation: 06/01/2024","start_date":" 06/01/2024","primary_txt":" Primary completion: 09/01/2027","primary_completion_date":" 09/01/2027","study_txt":" Completion: 04/01/2028","study_completion_date":" 04/01/2028","last_update_posted":"2024-04-26"},{"id":"41c64d00-75dd-4fa2-9ce1-9e342496ddc1","acronym":"ELAINE 1","url":"https://clinicaltrials.gov/study/NCT03781063","created_at":"2021-01-18T18:42:03.161Z","updated_at":"2024-07-02T16:35:08.944Z","phase":"Phase 2","brief_title":"Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation","source_id_and_acronym":"NCT03781063 - ELAINE 1","lead_sponsor":"Sermonix Pharmaceuticals Inc.","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 negative • ER mutation • ER Y537S • ER D538G • ESR1 mutation • ER Y537N • ER L536Q • ER Y537C","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • ER mutation • ER Y537S • ER D538G • ESR1 mutation • ER Y537N • ER L536Q • ER Y537C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • Fablyn (lasofoxifene)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 09/20/2019","start_date":" 09/20/2019","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-04-18"},{"id":"fab65276-bb46-4e33-bd0f-2cadd6a74b15","acronym":"","url":"https://clinicaltrials.gov/study/NCT04256941","created_at":"2021-01-18T20:41:27.231Z","updated_at":"2024-07-02T16:35:09.598Z","phase":"Phase 2","brief_title":"Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study","source_id_and_acronym":"NCT04256941","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" ER • PGR","pipe":" | ","alterations":" ER positive • HR positive • ER mutation • ER Y537S • ER D538G • ESR1 mutation","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HR positive • ER mutation • ER Y537S • ER D538G • ESR1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • Verzenio (abemaciclib) • Kisqali (ribociclib) • fulvestrant • letrozole • anastrozole"],"overall_status":"Completed","enrollment":" Enrollment 4","initiation":"Initiation: 05/31/2019","start_date":" 05/31/2019","primary_txt":" Primary completion: 09/22/2023","primary_completion_date":" 09/22/2023","study_txt":" Completion: 09/22/2023","study_completion_date":" 09/22/2023","last_update_posted":"2024-04-16"},{"id":"fa0a1bac-6932-4a6b-9fe9-e4d705b6bba8","acronym":"","url":"https://clinicaltrials.gov/study/NCT06064812","created_at":"2023-10-03T19:11:25.019Z","updated_at":"2024-07-02T16:35:33.307Z","phase":"Phase 1","brief_title":"A Phase I Clinical Trial of FWD1802 in Patients With ER+/HER2- BC.","source_id_and_acronym":"NCT06064812","lead_sponsor":"Forward Pharmaceuticals Co., Ltd.","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative • ER mutation • ESR1 mutation","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • ER mutation • ESR1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib)"],"overall_status":"Recruiting","enrollment":" Enrollment 99","initiation":"Initiation: 09/12/2023","start_date":" 09/12/2023","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2023-10-17"},{"id":"ebecf9c8-7521-4456-bb66-ff2f533a0378","acronym":"","url":"https://clinicaltrials.gov/study/NCT06062498","created_at":"2023-10-02T20:12:30.489Z","updated_at":"2024-07-02T16:35:35.109Z","phase":"Phase 2","brief_title":"Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer","source_id_and_acronym":"NCT06062498","lead_sponsor":"Northwestern University","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative • ER mutation • ESR1 mutation","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • ER mutation • ESR1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • Verzenio (abemaciclib) • Kisqali (ribociclib) • Orserdu (elacestrant)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 174","initiation":"Initiation: 09/30/2023","start_date":" 09/30/2023","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2023-10-02"},{"id":"3fa65445-060e-4ce9-9785-7480baa8f775","acronym":"PADA-1","url":"https://clinicaltrials.gov/study/NCT03079011","created_at":"2021-01-18T15:10:06.516Z","updated_at":"2024-07-02T16:35:36.038Z","phase":"Phase 3","brief_title":"PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection","source_id_and_acronym":"NCT03079011 - PADA-1","lead_sponsor":"UNICANCER","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative • ER mutation • ESR1 mutation","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • ER mutation • ESR1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • fulvestrant • letrozole • anastrozole • exemestane"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1017","initiation":"Initiation: 03/22/2017","start_date":" 03/22/2017","primary_txt":" Primary completion: 04/30/2021","primary_completion_date":" 04/30/2021","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2023-09-22"},{"id":"2f6706b3-4373-4123-bd41-4a6388aa2fbf","acronym":"","url":"https://clinicaltrials.gov/study/NCT04566393","created_at":"2021-01-18T21:48:48.647Z","updated_at":"2024-07-02T16:35:39.652Z","phase":"","brief_title":"Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies","source_id_and_acronym":"NCT04566393","lead_sponsor":"xCures","biomarkers":" BRAF • NRAS • HRAS • MAPK1","pipe":" | ","alterations":" BRAF mutation • ER mutation • HRAS mutation","tags":["BRAF • NRAS • HRAS • MAPK1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • ER mutation • HRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ulixertinib (BVD-523)"],"overall_status":"Available","enrollment":"","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2023-08-21"},{"id":"6ed06cab-c7c7-450b-93d9-67848afd9e45","acronym":"CICLADES","url":"https://clinicaltrials.gov/study/NCT03318263","created_at":"2021-01-18T16:23:13.868Z","updated_at":"2024-07-02T16:35:40.862Z","phase":"","brief_title":"CIrCuLAting Dna ESr1 Gene Mutations Analysis","source_id_and_acronym":"NCT03318263 - CICLADES","lead_sponsor":"Institut de Cancérologie de Lorraine","biomarkers":" HER-2 • ER • PIK3CA • AKT1","pipe":" | ","alterations":" ER positive • HER-2 negative • PIK3CA mutation • ER mutation • ESR1 mutation • AKT1 mutation • ER positive + HER-2 negative","tags":["HER-2 • ER • PIK3CA • AKT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • PIK3CA mutation • ER mutation • ESR1 mutation • AKT1 mutation • ER positive + HER-2 negative"],"overall_status":"Completed","enrollment":" Enrollment 146","initiation":"Initiation: 12/07/2017","start_date":" 12/07/2017","primary_txt":" Primary completion: 12/22/2022","primary_completion_date":" 12/22/2022","study_txt":" Completion: 12/22/2022","study_completion_date":" 12/22/2022","last_update_posted":"2023-08-04"},{"id":"17e179ba-af45-4910-b3e7-1e15f44c5d04","acronym":"","url":"https://clinicaltrials.gov/study/NCT05927779","created_at":"2023-07-03T16:10:23.510Z","updated_at":"2024-07-02T16:35:44.245Z","phase":"Phase 1/2","brief_title":"Study of TFX06 in Women With Advanced Breast Cancer.","source_id_and_acronym":"NCT05927779","lead_sponsor":"Shenzhen Yangli Pharmaceutical Technology Co., Ltd","biomarkers":" HER-2 • CDK4","pipe":" | ","alterations":" ER mutation • ESR1 mutation","tags":["HER-2 • CDK4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER mutation • ESR1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TFX06"],"overall_status":"Recruiting","enrollment":" Enrollment 74","initiation":"Initiation: 04/17/2023","start_date":" 04/17/2023","primary_txt":" Primary completion: 12/30/2024","primary_completion_date":" 12/30/2024","study_txt":" Completion: 04/30/2025","study_completion_date":" 04/30/2025","last_update_posted":"2023-06-30"},{"id":"4a21145c-913f-4666-866a-6508e1e7591f","acronym":"","url":"https://clinicaltrials.gov/study/NCT04174352","created_at":"2021-01-18T20:21:47.085Z","updated_at":"2024-07-02T16:35:45.655Z","phase":"Phase 1","brief_title":"FES Imaging to Optimize Tamoxifen for Metastatic Breast Cancer","source_id_and_acronym":"NCT04174352","lead_sponsor":"University of Wisconsin, Madison","biomarkers":" HER-2 • ER • CDK4","pipe":" | ","alterations":" HER-2 negative • ER mutation • ESR1 mutation • ER expression","tags":["HER-2 • ER • CDK4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • ER mutation • ESR1 mutation • ER expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen"],"overall_status":"Recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 10/20/2020","start_date":" 10/20/2020","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-06-15"},{"id":"ad9bd33c-6dd2-4321-9725-e38b95a50da8","acronym":"PADA-1","url":"https://clinicaltrials.gov/ct2/show/NCT03079011/","created_at":"2021-01-18T15:01:22.265Z","updated_at":"2022-10-07T18:55:12.223Z","phase":"Phase 3","brief_title":"PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection","source_id_and_acronym":"2016-004360-18 - PADA-1","lead_sponsor":"UNICANCER","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative • ER mutation","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • ER mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1017","initiation":"Initiation: 03/22/2017","start_date":" 03/22/2017","primary_txt":" Primary completion: 04/30/2021","primary_completion_date":" 04/30/2021","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2022-08-15"},{"id":"7abaedd7-8fbf-40ad-bbb9-d9b1ef0caeb6","acronym":"","url":"https://clinicaltrials.gov/study/NCT02913430","created_at":"2021-01-18T14:18:14.838Z","updated_at":"2024-07-02T16:36:27.482Z","phase":"Phase 1","brief_title":"Treatment of Metastatic Breast Cancer With Fulvestrant Plus Palbociclib or Tamoxifen Plus Palbociclib","source_id_and_acronym":"NCT02913430","lead_sponsor":"Shannon Puhalla","biomarkers":" ER","pipe":" | ","alterations":" ER mutation • ESR1 mutation","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER mutation • ESR1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • tamoxifen • fulvestrant"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 7","initiation":"Initiation: 04/24/2018","start_date":" 04/24/2018","primary_txt":" Primary completion: 10/28/2020","primary_completion_date":" 10/28/2020","study_txt":" Completion: 10/28/2021","study_completion_date":" 10/28/2021","last_update_posted":"2021-07-26"},{"id":"8dd4de40-6156-419d-9f72-41324509aa11","acronym":"FMER","url":"https://clinicaltrials.gov/study/NCT02473120","created_at":"2021-01-18T11:54:20.294Z","updated_at":"2024-07-02T16:36:42.616Z","phase":"","brief_title":"Study of ESR1 Mutations in Metastatic Breast Cancer","source_id_and_acronym":"NCT02473120 - FMER","lead_sponsor":"Centre Henri Becquerel","biomarkers":" ER","pipe":" | ","alterations":" ER mutation • ESR1 mutation","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER mutation • ESR1 mutation"],"overall_status":"Completed","enrollment":" Enrollment 104","initiation":"Initiation: 06/01/2015","start_date":" 06/01/2015","primary_txt":" Primary completion: 09/01/2019","primary_completion_date":" 09/01/2019","study_txt":" Completion: 10/01/2019","study_completion_date":" 10/01/2019","last_update_posted":"2020-07-30"},{"id":"36c39bba-f90e-4ec9-b285-fc30dd8481e3","acronym":"","url":"https://clinicaltrials.gov/study/NCT01781429","created_at":"2021-01-17T17:38:51.630Z","updated_at":"2024-07-02T16:36:47.933Z","phase":"Phase 1/2","brief_title":"Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies","source_id_and_acronym":"NCT01781429","lead_sponsor":"BioMed Valley Discoveries, Inc","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • NRAS mutation • ER mutation","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • NRAS mutation • ER mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ulixertinib (BVD-523)"],"overall_status":"Completed","enrollment":" Enrollment 136","initiation":"Initiation: 03/01/2013","start_date":" 03/01/2013","primary_txt":" Primary completion: 02/01/2018","primary_completion_date":" 02/01/2018","study_txt":" Completion: 09/01/2018","study_completion_date":" 09/01/2018","last_update_posted":"2020-03-20"},{"id":"84de35bd-d435-4d10-9e06-8c241fe78f57","acronym":"","url":"https://clinicaltrials.gov/study/NCT03202862","created_at":"2021-01-18T15:47:35.613Z","updated_at":"2024-07-02T16:37:20.527Z","phase":"Phase 2","brief_title":"The Efficacy of Fulvestrant in ESR1(Estrogen Receptor 1) Mutated Metastatic Breast Cancer","source_id_and_acronym":"NCT03202862","lead_sponsor":"Fudan University","biomarkers":" ER • PGR","pipe":" | ","alterations":" ER mutation • ER Y537S • ER D538G • ESR1 mutation • ER Y537N • ER Y537C","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER mutation • ER Y537S • ER D538G • ESR1 mutation • ER Y537N • ER Y537C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant"],"overall_status":"Unknown status","enrollment":" Enrollment 50","initiation":"Initiation: 07/01/2017","start_date":" 07/01/2017","primary_txt":" Primary completion: 06/01/2019","primary_completion_date":" 06/01/2019","study_txt":" Completion: 08/01/2019","study_completion_date":" 08/01/2019","last_update_posted":"2017-06-29"}]